Contact
searchSearch
HMP Global

First Report Managed Care

News

News
IMC Care Matches ICU Outcomes for Hypertensive Emergencies, Study Finds
05/04/2026
Rebecca Amrick
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with...
05/04/2026
First Report Managed Care
News
Adjuvant Immunotherapy Costs Challenge Lung Cancer Affordability
05/04/2026
Hannah Musick
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may...
05/04/2026
First Report Managed Care
News
Teclistamab Shows Comparable Efficacy but Lower Costs Than Elranatamab in RRMM Study
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
Glofitamab Emerges as an Accessible, High-Potential Alternative to CAR T Therapy in DLBCL
04/29/2026
Rebecca Amrick
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood...
04/29/2026
First Report Managed Care
News
Hemodialysis Triggers Wide Epigenetic Changes in Patients With Chronic Kidney Disease
04/27/2026
Rebecca Amrick
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study...
04/27/2026
First Report Managed Care
News
Sequencing of Bispecific Antibodies May Influence Outcomes in R/R Follicular Lymphoma
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Semaglutide Shows Health Benefits for CVD but Falls Short on Cost-Effectiveness at Current Drug Prices
04/23/2026
Rebecca Amrick
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that...
04/23/2026
First Report Managed Care
Behind the Bill
DOJ Places FDA-Approved Marijuana Products in Schedule III
04/23/2026
Grace Taylor, MS, MA
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice...
04/23/2026
First Report Managed Care

KOL Insights

CO
Interview
Behavioral Science as Infrastructure: Rethinking Adherence, Engagement, and Managed Care Decision-Making
04/23/2026
Chandra Y. Osborn, PhD, MPH
A member of our First Report Managed Care Editorial Advisory Board explains why managed care decisions hinge on confidence over speed—and how embedding behavioral science across the care continuum can close adherence gaps, activate patients,...
A member of our First Report Managed Care Editorial Advisory Board explains why managed care decisions hinge on confidence over speed—and how embedding behavioral science across the care continuum can close adherence gaps, activate patients,...
A member of our First Report...
04/23/2026
First Report Managed Care
Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
First Report Managed Care
Al B. Benson, III, MD, FACP, FASCO
Videos
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Evidence Review
03/31/2026
Al B. Benson, III, MD, FACP, FASCO
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the...
03/31/2026
First Report Managed Care
Regulatory Insights
A Turning Point in Health Policy: PBM Reform, Integration, and the Rise of DTC Drugs
03/30/2026
Adam Colborn, JD
New federal PBM reforms, heightened scrutiny of health care consolidation, and the expansion of direct-to-consumer drug models are poised to reshape the policy landscape, with uncertain implications for patient costs and market dynamics.
New federal PBM reforms, heightened scrutiny of health care consolidation, and the expansion of direct-to-consumer drug models are poised to reshape the policy landscape, with uncertain implications for patient costs and market dynamics.
New federal PBM reforms,...
03/30/2026
First Report Managed Care
MANAGED CARE Q&A
Why Emotional Readiness Matters in Specialty Drug Management
03/26/2026
Abby Reynolds, PharmD
In this interview, a guest expert explains why emotional readiness—not motivation or access alone—often determines whether patients can successfully initiate and persist on specialty therapies.
In this interview, a guest expert explains why emotional readiness—not motivation or access alone—often determines whether patients can successfully initiate and persist on specialty therapies.
In this interview, a guest...
03/26/2026
First Report Managed Care
MANAGED CARE Q&A
Beyond the Pharmacy Benefit: Managing Specialty Drug Costs in an Era of Rapid Growth
03/26/2026
Allison Oakes, PhD
A guest expert explains why specialty drugs dominating US spending is forcing payers to rethink benefit design, oncology strategy, and biosimilar adoption to control costs and improve value.
A guest expert explains why specialty drugs dominating US spending is forcing payers to rethink benefit design, oncology strategy, and biosimilar adoption to control costs and improve value.
A guest expert explains why...
03/26/2026
First Report Managed Care
ALH
Videos
Redefining gMG Management: Pt II
03/12/2026
Amanda L. Hernandez, MD, PhD
In the second part of this interview, Amanda Hernandez, MD, PhD, examines the role and limitations of Myasthenia Gravis Activities of Daily Living (MG-ADL)  and other outcome measures in myasthenia gravis, emphasizing the importance of...
In the second part of this interview, Amanda Hernandez, MD, PhD, examines the role and limitations of Myasthenia Gravis Activities of Daily Living (MG-ADL)  and other outcome measures in myasthenia gravis, emphasizing the importance of...
In the second part of this...
03/12/2026
First Report Managed Care
ALH
Videos
Redefining gMG Management: Pt I
03/12/2026
Amanda L. Hernandez, MD, PhD
In this interview, Amanda Hernandez, MD, PhD, discusses the evolving general myasthenia gravis (gMG) treatment landscape, highlighting the shift toward more targeted immunologic therapies, the challenges of step therapy, and the need for...
In this interview, Amanda Hernandez, MD, PhD, discusses the evolving general myasthenia gravis (gMG) treatment landscape, highlighting the shift toward more targeted immunologic therapies, the challenges of step therapy, and the need for...
In this interview, Amanda...
03/12/2026
First Report Managed Care
Real-World Data, Artificial Intelligence, Health Care
Commentary
Powering Actionable Insights With Real-Time RWD Dashboards
02/11/2026
Sujay Jadhav
Health care generates massive amounts of real-world data (RWD), and that volume is only continuing to expand. By 2030, the global big data analytics market is expected to reach nearly $350 billion, with health care driving much of that...
Health care generates massive amounts of real-world data (RWD), and that volume is only continuing to expand. By 2030, the global big data analytics market is expected to reach nearly $350 billion, with health care driving much of that...
Health care generates massive...
02/11/2026
First Report Managed Care
NSCLC, Oncology Coverage, Oncology Access
Videos
What PALOMA-3 Signals for Coverage, Access, and Care Delivery in NSCLC
02/02/2026
Narjust Florez, MD
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust...
02/02/2026
First Report Managed Care

Issue Features

Sponsored
Explore the Clinical Data for JOURNAVX® (suzetrigine)
10/16/2025
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid...
10/16/2025
First Report Managed Care
Infographic
Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis
08/06/2025
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the...
08/06/2025
First Report Managed Care
Feature Story
More Specialists Should Gravitate Toward Episode-Based Care Models
05/12/2025
Lynn Carroll; Rahul Sharma
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will...
05/12/2025
First Report Managed Care
Feature Story
Winning With Value-Based Care: Balancing Risk, Analytics, and Digital Innovation
05/12/2025
David J. Sand, MD, MBA; Lynn Carroll
Value-based care (VBC) is the future of health care. It is the best approach to improving patient outcomes, reducing costs and addressing overall population health through a focus on prevention, care coordination and overall wellness.
Value-based care (VBC) is the future of health care. It is the best approach to improving patient outcomes, reducing costs and addressing overall population health through a focus on prevention, care coordination and overall wellness.
Value-based care (VBC) is the...
05/12/2025
First Report Managed Care
Sponsored
The Teva Biosimilars Trend Report, Second Edition: Perspectives from Managed Care, Providers & Employers
03/27/2025
On behalf of Teva Pharmaceuticals, we are pleased to present the second edition of The Teva Biosimilars Trend Report. This report examines the latest issues, challenges, and developments in the rapidly evolving biosimilars market from the...
On behalf of Teva Pharmaceuticals, we are pleased to present the second edition of The Teva Biosimilars Trend Report. This report examines the latest issues, challenges, and developments in the rapidly evolving biosimilars market from the...
On behalf of Teva...
03/27/2025
First Report Managed Care

Interactive Features

Quiz
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Pre-Test
03/31/2026
03/31/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Quiz
Monitoring AI Automation
11/25/2025
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The...
11/25/2025
First Report Managed Care
Quiz
Mobile Health’s Expanding Role in Bridging Care Gaps Across the US
11/11/2025
11/11/2025
First Report Managed Care
Quiz
AI in Health Care: Potential and Pitfalls
11/11/2025
11/11/2025
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use